Published in Eur J Pharmacol on June 13, 2007
Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol (2009) 1.78
CaMKII in the cardiovascular system: sensing redox states. Physiol Rev (2011) 1.67
Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias. Circ Res (2012) 1.61
Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations. J Am Coll Cardiol (2011) 1.55
Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm (2008) 1.46
Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. Heart Rhythm (2011) 1.44
Arrhythmias, elicited by catecholamines and serotonin, vanish in human chronic atrial fibrillation. Proc Natl Acad Sci U S A (2014) 0.92
Ionic mechanisms of pacemaker activity in spontaneously contracting atrial HL-1 cells. J Cardiovasc Pharmacol (2011) 0.89
Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol (2010) 0.85
Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves. J Pharmacol Exp Ther (2010) 0.81
Cardiac calmodulin kinase: a potential target for drug design. Curr Med Chem (2011) 0.80
Pharmacological changes in cellular Ca2+ homeostasis parallel initiation of atrial arrhythmogenesis in murine Langendorff-perfused hearts. Clin Exp Pharmacol Physiol (2009) 0.80
Atrial remodelling in atrial fibrillation: CaMKII as a nodal proarrhythmic signal. Cardiovasc Res (2016) 0.79
Pulmonary Vein Sleeves as a Pharmacologic Model for the Study of Atrial Fibrillation. Electrofisiol Arritm (2010) 0.75
A Memory Molecule, Ca(2+)/Calmodulin-Dependent Protein Kinase II and Redox Stress; Key Factors for Arrhythmias in a Diseased Heart. Korean Circ J (2013) 0.75
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation (2005) 6.68
Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol (2009) 6.58
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol (2009) 3.18
Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J (2003) 3.06
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood (2010) 3.03
Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J (2011) 2.60
Atrial fibrillation and the risk of ischemic stroke: does it still matter in patients with a CHA2DS2-VASc score of 0 or 1? Stroke (2012) 2.27
Venice Chart international consensus document on atrial fibrillation ablation. J Cardiovasc Electrophysiol (2007) 2.25
Improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer: a United States population-based assessment. Cancer (2008) 2.19
Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. Circulation (2003) 2.17
The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials (2007) 2.16
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol (2012) 2.08
Isolation of multipotent cells from human term placenta. Stem Cells (2005) 2.03
Dabigatran and thrombin modulate electrophysiological characteristics of pulmonary vein and left atrium. Circ Arrhythm Electrophysiol (2012) 2.01
Loss of mXinalpha, an intercalated disk protein, results in cardiac hypertrophy and cardiomyopathy with conduction defects. Am J Physiol Heart Circ Physiol (2007) 1.99
Bifunctional magnetic silica nanoparticles for highly efficient human stem cell labeling. Nano Lett (2007) 1.91
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood (2009) 1.87
Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. J Am Coll Cardiol (2002) 1.87
CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. J Am Coll Cardiol (2011) 1.77
Sinus node dysfunction in atrial fibrillation patients: the evidence of regional atrial substrate remodelling. Europace (2012) 1.75
Relationship between the CHADS(2) score and risk of very late recurrences after catheter ablation of paroxysmal atrial fibrillation. Heart Rhythm (2012) 1.65
Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells (2006) 1.63
Effects of ivabradine on the pulmonary vein electrical activity and modulation of pacemaker currents and calcium homeostasis. J Cardiovasc Electrophysiol (2011) 1.60
Colon cancer, version 3.2014. J Natl Compr Canc Netw (2014) 1.59
Paradoxical long-term proarrhythmic effects after ablating the "head station" ganglionated plexi of the vagal innervation to the heart. Heart Rhythm (2013) 1.59
Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med (2010) 1.57
Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood (2010) 1.57
Frequency analysis in different types of paroxysmal atrial fibrillation. J Am Coll Cardiol (2006) 1.56
Maneuvers to decrease laparoscopy-induced shoulder and upper abdominal pain: a randomized controlled study. Arch Surg (2011) 1.56
Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. Int J Cardiol (2013) 1.56
Effects of aging and ouabain on left atrial arrhythmogenicity. J Cardiovasc Electrophysiol (2007) 1.55
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood (2011) 1.55
Electrophysiology of pulmonary veins. J Cardiovasc Electrophysiol (2006) 1.54
Successful catheter ablation reduces the risk of cardiovascular events in atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and higher. Europace (2012) 1.53
The different mechanisms between late and very late recurrences of atrial fibrillation in patients undergoing a repeated catheter ablation. J Cardiovasc Electrophysiol (2006) 1.53
Long-term outcome of catheter ablation in patients with atrial fibrillation originating from nonpulmonary vein ectopy. J Cardiovasc Electrophysiol (2012) 1.52
CHADS2 score and risk of new-onset atrial fibrillation: a nationwide cohort study in Taiwan. Int J Cardiol (2012) 1.51
Progressive remodeling of the atrial substrate--a novel finding from consecutive voltage mapping in patients with recurrence of atrial fibrillation after catheter ablation. J Cardiovasc Electrophysiol (2006) 1.49
Rectal cancer. J Natl Compr Canc Netw (2012) 1.49
Unilateral salpingo-oophorectomy as fertility-sparing surgery for borderline ovarian tumors. J Chin Med Assoc (2011) 1.48
Actual dose variation of parotid glands and spinal cord for nasopharyngeal cancer patients during radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.47
Morphological changes of the left atrial appendage after catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol (2006) 1.47
Acute effect of circumferential pulmonary vein isolation on left atrial substrate. J Cardiovasc Electrophysiol (2009) 1.46
Survival-weighted health profile for long-term survivors of acute myelogenous leukemia. Qual Life Res (2003) 1.46
Prevention of postlaparoscopic shoulder and upper abdominal pain: a randomized controlled trial. Obstet Gynecol (2013) 1.45
Heterogeneous expression of potassium currents and pacemaker currents potentially regulates arrhythmogenesis of pulmonary vein cardiomyocytes. J Cardiovasc Electrophysiol (2009) 1.45
High-resolution mapping around the crista terminalis during typical atrial flutter: new insights into mechanisms. J Cardiovasc Electrophysiol (2004) 1.45
Catheter ablation of atrial fibrillation versus atrioventricular junction ablation plus pacing therapy for elderly patients with medically refractory paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol (2005) 1.45
Validation of the frequency spectra obtained from the noncontact unipolar electrograms during atrial fibrillation. J Cardiovasc Electrophysiol (2007) 1.45
DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood (2011) 1.44
Renal dysfunction and the risk of thromboembolic events in patients with atrial fibrillation after catheter ablation--the potential role beyond the CHA₂DS₂-VASc score. Heart Rhythm (2012) 1.44
A novel finding- impairment of gastric myoelectricity after catheter ablation of atrial fibrillation. Circ J (2013) 1.43
Impact of right-ventricular apical pacing on the optimal left-ventricular lead positions measured by phase analysis of SPECT myocardial perfusion imaging. Eur J Nucl Med Mol Imaging (2014) 1.43
A clinical trial of 3 doses of transdermal 17beta-estradiol for preventing postmenopausal bone loss: a preliminary study. J Chin Med Assoc (2007) 1.41
Relationship between arrhythmogenic pulmonary veins and the surrounding atrial substrate in patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol (2010) 1.41
Heart failure enhances arrhythmogenesis in pulmonary veins. Clin Exp Pharmacol Physiol (2011) 1.41
A prospective, randomized comparison of modified pulmonary vein isolation versus conventional pulmonary vein isolation in patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol (2012) 1.39
Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation - An ENGAGE AF-TIMI 48 Subanalysis. Circ J (2016) 1.39
Paradoxical aging changes of the atrioventricular nodal properties in patients with atrioventricular nodal re-entrant tachycardia. Circ J (2011) 1.39
Unusual phenomenon of spontaneous termination of atrioventricular nodal reentrant tachycardia with 2:1 atrioventricular block. J Cardiovasc Electrophysiol (2003) 1.39
Heat-stress responses modulate beta-adrenergic agonist and angiotensin II effects on the arrhythmogenesis of pulmonary vein cardiomyocytes. J Cardiovasc Electrophysiol (2011) 1.39
Noncontact three-dimensional mapping guides catheter ablation of difficult atrioventricular nodal reentrant tachycardia. Int J Cardiol (2006) 1.39
Seasonal variation in the frequency of sudden cardiac death and ventricular tachyarrhythmia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: the effect of meteorological factors. Heart Rhythm (2013) 1.38
Mechanism of adenosine-induced termination of focal atrial tachycardia. J Cardiovasc Electrophysiol (2004) 1.38
Mesoporous silica nanoparticles as a delivery system of gadolinium for effective human stem cell tracking. Small (2008) 1.37
Highly efficient cellular labeling of mesoporous nanoparticles in human mesenchymal stem cells: implication for stem cell tracking. FASEB J (2005) 1.37
Calcium overload and cardiac function. J Biomed Sci (2004) 1.34
Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res (2006) 1.31
Electrophysiological characteristics and catheter ablation in patients with paroxysmal right atrial fibrillation. Circulation (2005) 1.31